6. STD Kits 7. Histoid leprosy; Lucio leprosy 8. Rehabilitation in leprosy; Atypical presentation of Pauci bacillary leprosy 9. Prenatal syphilis; Ulcerative STD and HIV coinfection 10. STD investigations; Gonorrhoea complications in 10 marks format for 3rd yr dermatology post graduate theory examination

Reading File

Now I'll run all searches in parallel to maximize efficiency within my budget.

Finding Sources

Good data retrieved. Now let me get the detailed content from the key files identified:

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Here are all five answers in proper 10-mark format for 3rd year Dermatology PG theory examination:

3rd Year Dermatology PG Theory Examination - Model Answers

Q6. STD Kits (10 Marks)

Introduction

STD kits (Syndromic Treatment Kits) are pre-packaged drug combinations used for syndromic management of sexually transmitted diseases at the point of care, without waiting for laboratory results. This approach is used especially in resource-limited settings.

Rationale for STD Kits

STDs are often mixed infections; syndromic approach treats all likely pathogens simultaneously
Reduces loss to follow-up (treatment given at first contact)
Cost-effective for primary health care settings
Recommended by WHO and national STD control programs
Prevents complications and interrupts transmission chain

Types of STD Kits (as per NACO / National STD Program)

Kit	Syndrome	Contents
Kit 1	Urethral discharge (male)	Tab. Ciprofloxacin 500 mg (single dose) + Tab. Doxycycline 100 mg BD x 7 days (or Azithromycin 1g single dose)
Kit 2	Vaginal discharge	Tab. Fluconazole 150 mg + Tab. Metronidazole 400 mg BD x 7 days + Tab. Ciprofloxacin 500 mg single dose
Kit 3	Genital ulcer disease	Tab. Ciprofloxacin 500 mg BD x 3 days + Tab. Benzathine penicillin 2.4 MU IM single dose (or Azithromycin 1g)
Kit 4	Inguinal bubo	Tab. Doxycycline 100 mg BD x 21 days + Tab. Ciprofloxacin 500 mg BD x 3 days
Kit 5	Lower abdominal pain (PID)	Tab. Metronidazole 400 mg BD x 14 days + Tab. Doxycycline 100 mg BD x 14 days + Tab. Ciprofloxacin 500 mg

Limitations

Overtreatment / polypharmacy
Does not identify specific pathogen
May contribute to antibiotic resistance
Not suitable for treatment failures or complications
Does not replace laboratory-based management when resources are available

Partner Treatment

All kits include partner treatment packs. This is critical for interrupting transmission chains and preventing reinfection.

Q7. Histoid Leprosy; Lucio Leprosy (10 Marks)

HISTOID LEPROSY (5 Marks)

Definition: Histoid leprosy is a clinically distinct, rarely reported variant of multibacillary (lepromatous) leprosy with unusually high bacillary load, first described by Wade in 1963.

Etiopathogenesis:

Arises from: (a) Dapsone monotherapy resistance/relapse, (b) de novo in some treatment-naive patients
The bacilli undergo adaptation, producing spindle-cell granulomas

Clinical Features:

Smooth, shiny, hemispherical, dome-shaped, nontender, soft-to-firm nodules
Subcutaneous, superficial, or fixed to deeper structures
Lesions appear on otherwise normal-looking skin (intervening skin is normal - key feature)
Located on face, back, buttocks, extremities, and over bony prominences (elbows, knees)
Number: few to several hundred
Some nodules may umbilicate; some coalesce into annular patterns
Dermatofibroma-like papules and nodules are characteristic

Histopathology:

Spindle-shaped (histiocytic) cells arranged in storiform pattern - pathognomonic
Unusually large numbers of acid-fast bacilli (AFB), including globi (rafts of bacilli)
Bacillary index (BI) higher than in ordinary LL leprosy

Diagnosis:

Slit-skin smear: very high BI
Biopsy: spindle-cell granuloma with massive AFB load
Requires high index of suspicion as it mimics many dermatologic conditions (dermatofibroma, xanthoma, neurofibroma)

Treatment: MDT for multibacillary leprosy (WHO MB-MDT: Rifampicin + Clofazimine + Dapsone for 12 months)

Significance: High bacillary load patients serve as reservoirs of infection; early diagnosis and treatment is essential.

LUCIO LEPROSY (5 Marks)

Definition: Lucio leprosy (also called "diffuse leprosy of Lucio and Latapi" or "lepra bonita" - "beautiful leprosy") is a non-nodular, diffuse form of lepromatous leprosy caused by Mycobacterium lepromatosis, geographically restricted to Mexico and Central America (occasionally seen on the US Gulf coast).

Etiology: M. lepromatosis - a distinct species that specifically invades endothelial cells (unlike M. leprae). This endothelial tropism is the key pathogenetic mechanism.

Clinical Features:

Diffuse, smooth, waxy, shiny skin infiltration (hence "lepra bonita")
Obvious diffuse infiltration of ear lobes and forehead
Loss of eyebrows (madarosis) and sometimes eyelashes and all body hair
Hoarse voice (laryngeal infiltration)
Numbness and edema of hands and feet (mimicking myxedema)
Notably: NO discrete nodules, NO lymphadenopathy, NO arthritis (differentiates from ENL)

The Lucio Phenomenon:

A severe reactional state unique to Lucio leprosy
Presents as multiple well-defined, angular, jagged purpuric lesions
Evolves into massive ulcerations that spread in ascending fashion over extremities
Heals with atrophic scarring
Pathogenesis: endothelial cell injury leading to thrombosis and infarction
Treatment: poorly responsive to corticosteroids and thalidomide; effective antimicrobial chemotherapy for lepromatous leprosy is the only recommended treatment, combined with wound management

Histopathology: Endothelial cell invasion by bacilli, fibrin thrombi, ischemic necrosis

Differentiating Features - Lucio Leprosy vs ENL:

Feature	Lucio Leprosy	ENL (Type 2 Reaction)
Geography	Mexico/Central America	Worldwide
Lesions	Diffuse, no nodules	Tender nodules
Reaction	Lucio phenomenon (purpura/ulcers)	Erythema nodosum leprosum
Nodules	Absent	Present
Organism	M. lepromatosis	M. leprae

Q8. Rehabilitation in Leprosy; Atypical Presentation of Paucibacillary Leprosy (10 Marks)

REHABILITATION IN LEPROSY (6 Marks)

Introduction: Rehabilitation is a major component of the National Leprosy Eradication Programme (NLEP) under the Disability Prevention and Medical Rehabilitation (DPMR) component.

WHO Disability Grading in Leprosy:

Grade	Hands/Feet	Eyes
0	No anesthesia, no deformity	No problem
1	Anesthesia present, no visible damage	Decreased vision
2	Visible damage/deformity	Severe visual impairment (< 6/60)

Levels of Rehabilitation:

1. Medical Rehabilitation:

Prevention of disability by early diagnosis and prompt MDT
Ulcer care kits: dressing materials, supportive medicines for leprosy patients with ulcers/wounds (provided under NLEP including to leprosy colonies)
Micro-cellular rubber (MCR) footwear: protects insensitive feet from plantar ulcers
Steroid therapy for reactions (Type 1 and ENL) to prevent nerve damage
Physiotherapy: active and passive exercises to prevent contractures

2. Surgical Rehabilitation (Reconstructive Surgery - RCS):

Correction of lagophthalmos: tarsal strip/lateral tarsorrhaphy
Correction of claw hand: tendon transfer procedures
Correction of foot drop: tibialis posterior transfer
Correction of wrist drop, thumb opposition deformity
Under NLEP: 83 centers (41 NGOs + 42 Government Medical Colleges) conducting RCS
Financial incentive: Rs. 5,000 per patient from BPL families undergoing RCS; Rs. 5,000 support per surgery to government institutions

3. Socio-economic Rehabilitation:

Self-care groups and vocational training
Micro-credit schemes
Anti-stigma campaigns (IEC activities)
NGO involvement (ILEP - International Federation of Anti-Leprosy Associations supports 36 NGOs for RCS)
Persons affected by leprosy are eligible for other welfare schemes

4. Community-Based Rehabilitation (CBR):

Involvement of ASHA workers in detection and treatment completion
Household contact surveys
Integration with general health care system (since 2002-03)
Primary level DPMR: wound care, MCR footwear, referral for RCS
Secondary/tertiary level: RCS centers, PMR centers

ATYPICAL PRESENTATIONS OF PAUCIBACILLARY (PB) LEPROSY (4 Marks)

Definition: Paucibacillary leprosy includes indeterminate, tuberculoid (TT), and borderline tuberculoid (BT) forms - characterized by 1-5 skin lesions and/or 1 nerve trunk involvement, with negative slit-skin smear.

Atypical Presentations:

Pure Neuritic (Neural) Leprosy:
- Sensory loss along distribution of an involved nerve trunk ± motor deficit
- No skin lesions whatsoever
- Accounts for 5-10% of all leprosy in India and Nepal
- Nerve involvement may be single or multiple, generally asymmetrical
- Up to 1/3 patients later develop skin lesions
- Diagnosis: nerve biopsy showing granulomas
Histoid-like Presentation in PB Leprosy: Rarely, TT or BT lesions may present as raised, firm plaques or nodules rather than flat hypopigmented patches
Solitary Lesion Leprosy (Single Patch Leprosy):
- Only one skin lesion, may be hypo/hyperpigmented
- Sometimes with/without neurological deficit
- Treatment: Single dose ROM (Rifampicin 600mg + Ofloxacin 400mg + Minocycline 100mg)
Reactional States as Presenting Feature:
- Type 1 reaction (Reversal Reaction) may be the first presentation
- Sudden onset of erythema, swelling, new lesions with neuritis
- Patient may not have noticed the original patch
Mimickers / Diagnostic Pitfalls:
- Mimics tinea versicolor, vitiligo, pityriasis alba, discoid lupus
- Annular lesions of BB may be confused with granuloma annulare
- Hypoesthetic, hypopigmented plaques with anhidrosis are the clue
Leprosy in Special Sites: Earlobe, eyebrow, mucosal (nasal) - mimicking other dermatoses

Q9. Prenatal Syphilis; Ulcerative STD and HIV Coinfection (10 Marks)

PRENATAL (CONGENITAL) SYPHILIS (6 Marks)

Epidemiology:

Congenital syphilis has resurged globally, especially in sub-Saharan Africa where prenatal testing is not universally available
~21% of all perinatal deaths in sub-Saharan Africa are attributable to congenital syphilis
Risk groups: mothers with no prenatal care, crack cocaine users, sex workers

Pathogenesis:

Treponema pallidum crosses the placenta from an infected mother (usually with early syphilis)
Placental infection does NOT occur before the 4th month of gestation (Langhans cell layer acts as barrier)
Therefore: treatment before the end of 2nd trimester almost always prevents adverse outcomes
Risk of adverse outcome from untreated early maternal syphilis: 40% fetal death/miscarriage; 40% syphilitic infant

Classification:

Early congenital syphilis: clinical manifestations within first 2 years of life
Late congenital syphilis: manifestations after age 2 years

Clinical Features of Early Congenital Syphilis:

Two-thirds of neonates appear normal at birth (detected only serologically)
Snuffles (syphilitic rhinitis): Most frequent, earliest sign - blood-stained nasal discharge, nasal obstruction; progressive ulceration can cause saddle nose deformity
Cutaneous lesions (30-60%): Resemble secondary acquired syphilis - morbilliform rash initially, fading to copper-brown; also bullous lesions (pemphigus syphiliticus) especially on palms/soles
Mucous patches, condylomata lata
Hepatosplenomegaly, jaundice (liver involvement)
Osteochondritis / periostitis (Wimberger sign - bilateral destruction of medial tibial metaphyses)
Pseudoparalysis of Parrot: limb immobility from osteochondritis pain
CNS involvement: meningitis, hydrocephalus
Marasmic, fretful neonate with "old man face" appearance

Clinical Features of Late Congenital Syphilis:

Interstitial keratitis (most common - 40-80%)
Hutchinson's teeth (notched, barrel-shaped upper central incisors)
8th nerve deafness
These three = Hutchinson's Triad
Bone/joint: Saber shins (anterior bowing of tibia), Clutton's joints (painless synovitis)
Saddle nose deformity, Rhagades (perioral linear scars)
Neurosyphilis: juvenile tabes, seizures
Cardiovascular: rare in congenital form

Screening:

All pregnant women screened at first antenatal visit AND at delivery
Low-tech point-of-care tests (RPR/VDRL) used in resource-poor settings

Treatment of Congenital Syphilis:

Neonates/infants: Aqueous crystalline penicillin G 200,000-300,000 U/kg/day IV/IM (50,000 U/kg every 4-6 hours) for 10-14 days
Older children: Same regimen or benzathine penicillin G 50,000 U/kg IM single dose (max 2.4 MU)
Pregnant mothers with syphilis: Benzathine penicillin G 2.4 MU IM (dose appropriate to stage); a second dose 1 week later may be given
Penicillin is the ONLY drug proven effective for congenital syphilis; no alternatives validated in pregnancy

Common Failures in Prevention:

Lack of documented treatment of syphilis before pregnancy
Absence of serologic testing during pregnancy
Late or no maternal treatment
Use of non-penicillin regimens

ULCERATIVE STD AND HIV COINFECTION (4 Marks)

Mechanism of Increased HIV Risk with Genital Ulcer Disease (GUD):

Genital ulcerative STDs significantly amplify HIV transmission bidirectionally:

In HIV-negative individuals (increased acquisition):

Genital ulcers breach mucosal integrity, removing the first line of defense
HIV-positive immune cells (CD4+ T cells, macrophages) are recruited to the ulcer site
Concentrated inflammatory infiltrate at the ulcer provides a highly susceptible target for HIV entry
Estimated increase in HIV acquisition risk: 2-5 fold per sex act

In HIV-positive individuals (increased transmission):

HIV is shed in high concentrations in genital ulcer exudate
HSV-2 shedding is increased in HIV+ persons (HSV-2 affects 50-90% of HIV-positive patients)
Ulceration increases local viral load in genital secretions

Specific STD-HIV interactions:

Ulcerative STD	Causative Agent	HIV Interaction
Genital Herpes (HSV-2)	Herpes simplex virus 2	Most important cofactor globally; affects 50-90% of HIV+; bidirectional amplification
Syphilis	Treponema pallidum	Coinfection increases HIV viral load AND decreases CD4 count, accelerating immunosuppression
Chancroid	Haemophilus ducreyi	Highly associated with HIV transmission in sub-Saharan Africa
Lymphogranuloma Venereum	Chlamydia trachomatis L1-L3	Creates bubo/ulcer facilitating HIV entry
Donovanosis	Klebsiella granulomatis	Extensive ulceration acts as HIV entry portal

Clinical Implications:

All patients diagnosed with GUD should be offered HIV testing
Treatment of GUD reduces HIV transmission at the population level
Syndromic management must cover all causes simultaneously
Suppressive antiviral therapy (Acyclovir 400mg BD) for HSV-2 in HIV+ patients reduces both HIV shedding and HSV recurrences
Condom promotion is essential

Q10. STD Investigations; Gonorrhoea Complications (10 Marks)

STD INVESTIGATIONS (5 Marks)

STD investigations are classified by the category of pathogen and the type of test.

A. Syndromic vs. Etiologic Approach:

Syndromic: Treat empirically based on clinical syndrome (used at primary care level)
Etiologic/laboratory-based: Used at referral centers and for complicated cases

B. Laboratory Investigations by Pathogen:

1. Gonorrhoea (Neisseria gonorrhoeae):

Gram stain of urethral/cervical discharge: Gram-negative intracellular diplococci (sensitivity 90-95% in symptomatic male urethritis; only 50% in females)
Culture on Thayer-Martin medium (chocolate agar with antibiotics) - gold standard; allows sensitivity testing
NAAT (Nucleic Acid Amplification Tests): Most sensitive and specific; can use urine, urethral, cervical, rectal, pharyngeal swabs; replaces culture in many settings

2. Chlamydia (Chlamydia trachomatis):

NAAT: First-line investigation - urine or genital swab
Cell culture: Gold standard historically, but technically demanding
ELISA/EIA: Antigen detection - less sensitive than NAAT
MIF (Microimmunofluorescence): For LGV serology

3. Syphilis (Treponema pallidum):

Non-treponemal tests (NTT): VDRL, RPR - used for screening and monitoring treatment response; can give false positives
Treponemal tests: TPHA, FTA-ABS, TPPA - confirmatory; remain positive lifelong
Dark-field microscopy: Direct visualization of T. pallidum from primary/secondary lesions; gold standard for primary chancre
PCR: Available in specialized centers

4. Genital Herpes (HSV):

Viral culture from vesicle/ulcer base: gold standard but less sensitive in healing lesions
Tzanck smear: Multinucleated giant cells - rapid, simple, low sensitivity
NAAT/PCR: Most sensitive, especially for late/atypical lesions
Type-specific serology (IgG): HSV-1 vs HSV-2; useful for diagnosis between episodes

5. HPV / Genital Warts:

Primarily clinical diagnosis
Acetowhitening (5% acetic acid) - improves visualization of subclinical lesions
Colposcopy + Biopsy: For suspicious/atypical lesions
HPV DNA PCR/typing: For high-risk strains (HPV 16, 18)
Pap smear / liquid-based cytology: Cervical cancer screening

6. Chancroid (H. ducreyi):

Culture on selective media (enriched chocolate agar): sensitivity only 50-60%
NAAT where available
Clinical diagnosis most common (diagnosis of exclusion after ruling out syphilis and herpes)

7. Trichomonas:

Wet mount: Direct visualization of motile trichomonads (sensitivity 60-70%)
Culture: InPouch TV culture system - gold standard
NAAT: Highest sensitivity

8. HIV Testing (mandatory in all STD patients):

4th generation Ag/Ab combo assay (screening)
Western blot / NAAT (confirmatory)
CD4 count and viral load (staging and monitoring)

GONORRHOEA COMPLICATIONS (5 Marks)

Causative Agent: Neisseria gonorrhoeae - Gram-negative intracellular diplococcus

Complications are classified as Local, Regional, and Systemic (Disseminated):

A. LOCAL COMPLICATIONS IN MALES:

Epididymo-orchitis: Most common serious complication in men; presents as unilateral scrotal pain, swelling, tenderness; may lead to infertility
Prostatitis: Urinary retention, perineal pain, tender boggy prostate on PR
Cowperitis (Cowper's gland abscess): Perineal swelling, pain on defecation
Tysonitis: Infection of Tyson's glands (preputial glands)
Periurethral abscess / Urethral stricture: Late complication from scarring of anterior urethra
Balanitis / Posthitis: Secondary infection

B. LOCAL COMPLICATIONS IN FEMALES:

Bartholinitis/Bartholin's abscess: Unilateral swelling at 5 or 7 o'clock position at vulva; extremely tender
Skenitis: Paraurethral gland infection
Cervicitis: Mucopurulent discharge, contact bleeding
Endometritis: Abnormal uterine bleeding, pelvic pain
Pelvic Inflammatory Disease (PID): Most important complication

PID from Gonorrhoea:

Caused by ascending infection to fallopian tubes
Salpingitis, tubo-ovarian abscess, perihepatitis (Fitz-Hugh-Curtis syndrome: violin-string adhesions between liver capsule and anterior abdominal wall)
Consequences of PID:
- Infertility (25% after one episode, 50% after two, 75% after three episodes)
- Ectopic pregnancy (10x increased risk)
- Chronic pelvic pain
- Recurrent PID

C. NEONATAL COMPLICATIONS:

Ophthalmia neonatorum (Gonococcal conjunctivitis): Acquired during passage through infected birth canal; purulent conjunctivitis within 2-5 days of birth; can rapidly progress to corneal ulceration, perforation, and blindness
- Prophylaxis: 1% silver nitrate (Credé's method) or erythromycin/tetracycline eye ointment at birth
- Treatment: Ceftriaxone 25-50 mg/kg IV single dose

D. DISSEMINATED GONOCOCCAL INFECTION (DGI):

Occurs in 0.5-3% of untreated gonorrhoea; more common in women

Two syndromes:

Bacteremic phase (Arthritis-Dermatitis syndrome):
- Tenosynovitis (especially hands, wrists, ankles) - pathognomonic
- Dermatitis: scattered pustular, vesicular, or hemorrhagic papules/pustules on extremities (1-20 lesions)
- Polyarthralgias
- Blood cultures often positive
Septic arthritis phase:
- Purulent monoarthritis (knee most common; also wrist, ankle)
- Blood cultures usually negative; joint fluid positive
- Permanent joint damage if untreated

Rare DGI manifestations:

Gonococcal meningitis
Gonococcal endocarditis (aortic valve most commonly affected; high mortality)
Gonococcal perihepatitis (Fitz-Hugh-Curtis syndrome)

E. PHARYNGEAL AND ANORECTAL GONORRHOEA:

Usually asymptomatic
Can serve as reservoir for reinfection and transmission
Pharyngeal gonorrhoea: source of DGI; difficult to eradicate

Summary Table - Gonorrhoea Complications:

Site	Complication	Key Feature
Male urethra	Stricture, periurethral abscess	Late, scarring
Epididymis	Epididymo-orchitis	Infertility risk
Female (lower tract)	Bartholinitis, cervicitis	Common
Female (upper tract)	PID, salpingitis	Infertility, ectopic
Peritoneum	Fitz-Hugh-Curtis	Violin-string adhesions
Neonate	Ophthalmia neonatorum	Risk of blindness
Systemic	DGI - arthritis-dermatitis	Tenosynovitis + pustules
Systemic (severe)	Endocarditis, meningitis	Rare, high mortality

Treatment of Gonorrhoea (CDC/WHO 2024):

Uncomplicated urogenital/anorectal: Ceftriaxone 500 mg IM single dose (1g if body weight >150 kg)
If chlamydia not excluded, add Doxycycline 100 mg BD x 7 days
DGI: Ceftriaxone 1g IV/IM daily for 7 days (minimum)
Gonococcal endocarditis/meningitis: Ceftriaxone 1-2g IV every 12-24 hours for 4 weeks
Resistance: Fluoroquinolone and penicillin resistance now widespread; cephalosporin-resistant strains (XDR-GC) emerging globally

*Sources: Goldman-Cecil Medicine (International Ed.); Fitzpatrick's Dermatology (8th ed.); Dermatology 2-Volume Set (Lebwohl, 5th ed.); Andrews' Diseases of the Skin; Harrison's Principles of Internal Medicine (22nd ed., 2025); Park's Textbook of Preventive and Social Medicine; Campbell-Walsh Urology.*All five model answers are ready. Here is a quick guide to what each answer covers:

Quick Reference Summary:

Q6 - STD Kits: Covers the rationale for syndromic management, all 5 NACO kit compositions (urethral discharge, vaginal discharge, genital ulcer, inguinal bubo, PID), partner treatment packs, and limitations.

Q7 - Histoid & Lucio Leprosy: Histoid leprosy (Wade, 1963) - spindle-cell granuloma, high BI, dermatofibroma-like nodules on normal-looking skin. Lucio leprosy - M. lepromatosis, diffuse non-nodular "lepra bonita," Lucio phenomenon (ascending purpura/ulceration), endothelial pathogenesis, poorly responsive to steroids/thalidomide.

Q8 - Rehabilitation in Leprosy & Atypical PB Leprosy: Four levels of rehab (medical/DPMR, surgical/RCS, socioeconomic, CBR); WHO disability grading; NLEP specifics (83 RCS centers, MCR footwear, ulcer kits, ASHA). Atypical PB leprosy includes pure neuritic, single lesion, reactional presentation, and mimickers.

Q9 - Prenatal Syphilis & Ulcerative STD-HIV Coinfection: Full Hutchinson's triad, early vs late congenital syphilis, snuffles, periostitis, penicillin dosing in neonates; plus the bidirectional HSV-2/syphilis/chancroid HIV amplification mechanism with risk quantification.

Q10 - STD Investigations & Gonorrhoea Complications: Complete lab panel by pathogen (NAAT, dark-field, Thayer-Martin culture, VDRL/TPHA, PCR). Gonorrhoea complications from Bartholinitis and PID (with Fitz-Hugh-Curtis) to DGI arthritis-dermatitis syndrome, ophthalmia neonatorum, endocarditis/meningitis, plus current ceftriaxone-based treatment.

Can you generate the test again for question above

Here are all five model answers regenerated in full 10-mark format for 3rd Year Dermatology PG Theory Examination:

3rd Year Dermatology PG Theory Examination - Model Answers

Q6. STD Kits (10 Marks)

Introduction

STD kits (Syndromic Treatment Kits) are pre-packaged drug combinations used for syndromic management of sexually transmitted diseases at the point of first contact, without waiting for laboratory results. Recommended by WHO and adopted under the National AIDS Control Programme (NACP/NACO).

Rationale for Syndromic Approach

STDs are often mixed infections; treating all likely pathogens simultaneously improves outcomes
Reduces loss to follow-up - treatment given at the first visit
Cost-effective at primary health care level
Prevents complications and interrupts transmission chain
Particularly valuable in resource-limited settings where lab infrastructure is absent

Types of STD Kits (NACO, India)

Kit	Syndrome	Drug Contents
Kit 1	Urethral discharge (male)	Tab. Ciprofloxacin 500 mg single dose + Tab. Doxycycline 100 mg BD x 7 days (or Azithromycin 1g single dose)
Kit 2	Vaginal discharge	Tab. Fluconazole 150 mg single dose + Tab. Metronidazole 400 mg BD x 7 days + Tab. Ciprofloxacin 500 mg single dose
Kit 3	Genital ulcer disease	Tab. Ciprofloxacin 500 mg BD x 3 days + Benzathine penicillin 2.4 MU IM single dose (or Azithromycin 1g)
Kit 4	Inguinal bubo	Tab. Doxycycline 100 mg BD x 21 days + Tab. Ciprofloxacin 500 mg BD x 3 days
Kit 5	Lower abdominal pain (PID)	Tab. Metronidazole 400 mg BD x 14 days + Tab. Doxycycline 100 mg BD x 14 days + Tab. Ciprofloxacin 500 mg BD x 14 days

Partner Treatment

All kits include a partner treatment pack
Partners are treated presumptively without clinical assessment
Critical for interrupting the transmission chain and preventing reinfection

Limitations of STD Kits

Overtreatment and polypharmacy
Cannot identify specific pathogen
May contribute to antibiotic resistance with widespread use
Not suitable for treatment failures, complicated cases, or pregnancy
Does not replace laboratory-based management when resources are available
No kit covers ectoparasites (scabies, pubic lice) - require separate treatment

Q7. Histoid Leprosy; Lucio Leprosy (10 Marks)

HISTOID LEPROSY (5 Marks)

Definition: Histoid leprosy is a clinically and histologically distinct, rare variant of multibacillary (lepromatous) leprosy with an unusually high bacillary load, first described by Wade in 1963.

Etiopathogenesis:

Classically arises in patients on dapsone monotherapy due to drug resistance/relapse
Also seen de novo in treatment-naive patients
Bacilli adapt and produce characteristic spindle-shaped histiocytic cells
Bacillary index (BI) is higher than in ordinary lepromatous leprosy

Clinical Features:

Smooth, shiny, hemispherical, dome-shaped, nontender, soft-to-firm nodules
Lesions appear on otherwise normal-looking skin (key differentiating feature)
Subcutaneous, superficial, or fixed to deeper structures
Sites: Face, back, buttocks, extremities, over bony prominences (especially elbows and knees)
Number: few to several hundred
May umbilicate; some coalesce into annular patterns
Resembles dermatofibroma, xanthoma, or neurofibroma clinically

Histopathology (Pathognomonic):

Spindle-shaped (fusiform) histiocytic cells in storiform pattern - hallmark feature
Unusually large numbers of AFB, including globi (rafts/packets of bacilli)
BI much higher than ordinary LL leprosy

Diagnosis:

Slit-skin smear: very high BI
Skin biopsy: spindle-cell granuloma confirms diagnosis
High index of suspicion required as it mimics many dermatologic conditions

Significance: High bacillary load patients serve as reservoirs of infection; early diagnosis and treatment is essential for public health.

Treatment: WHO MB-MDT (Rifampicin 600 mg monthly + Clofazimine 300 mg monthly and 50 mg daily + Dapsone 100 mg daily) for 12 months.

LUCIO LEPROSY (5 Marks)

Definition: Lucio leprosy (also called "diffuse leprosy of Lucio and Latapi" or "lepra bonita" - "beautiful leprosy") is a non-nodular, diffuse form of lepromatous leprosy caused by Mycobacterium lepromatosis, geographically restricted mainly to Mexico and Central America (occasionally US Gulf coast).

Etiology:

Caused by M. lepromatosis - a distinct species closely related to but different from M. leprae
Key pathogenesis: endothelial cell invasion by bacilli (unlike M. leprae)
This endothelial tropism underpins both the clinical appearance and the Lucio phenomenon

Clinical Features:

Diffuse, smooth, waxy, shiny skin infiltration (hence "lepra bonita")
Obvious diffuse infiltration of ear lobes and forehead
Madarosis (loss of eyebrows and eyelashes) and sometimes all body hair
Hoarse voice (laryngeal infiltration)
Numbness and edema of hands and feet (may mimic myxedema)
Crucially: NO discrete nodules, NO lymphadenopathy, NO arthritis - this differentiates it from ENL

The Lucio Phenomenon (Reactional State):

A severe, specific reactional state unique to Lucio leprosy
Presents as multiple, well-defined, angular, jagged purpuric lesions
Evolves into massive ulcerations that spread in ascending fashion over extremities
Heals with atrophic scarring
Pathogenesis: Endothelial injury → fibrin thrombi → ischemic infarction → ulceration
Treatment: Poorly responsive to corticosteroids and thalidomide; effective antimicrobial chemotherapy (MB-MDT) is the only recommended treatment, combined with wound management for leg ulcers

Histopathology: Endothelial cells packed with bacilli, fibrin thrombi in dermal vessels, ischemic necrosis of overlying epidermis

Differentiating Lucio Leprosy vs ENL:

Feature	Lucio Leprosy	ENL (Type 2 Reaction)
Geographic distribution	Mexico/Central America	Worldwide
Skin lesions	Diffuse, no nodules	Tender erythematous nodules
Reactional state	Lucio phenomenon (purpura, ulcers)	ENL
Nodules	Absent	Present
Causative organism	M. lepromatosis	M. leprae
Response to steroids	Poor	Good

Q8. Rehabilitation in Leprosy; Atypical Presentation of Paucibacillary Leprosy (10 Marks)

REHABILITATION IN LEPROSY (6 Marks)

Introduction: Rehabilitation is an integral component of the National Leprosy Eradication Programme (NLEP) under the Disability Prevention and Medical Rehabilitation (DPMR) component. The goal is not only to treat the disease but to restore function and social participation.

WHO Disability Grading in Leprosy:

Grade	Hands/Feet	Eyes
0	No anesthesia, no visible deformity	No eye problem
1	Anesthesia present, no visible damage	Decreased vision but can count fingers at 6 meters
2	Visible damage/deformity	Severe visual impairment (cannot count fingers at 6 m) or lagophthalmos

Four Levels of Rehabilitation:

1. Medical Rehabilitation (Prevention of Disability - POD):

Early diagnosis and prompt MDT to prevent nerve damage
Treatment of reactions (Type 1 and ENL) with steroids to prevent irreversible nerve damage
Ulcer care kits: Dressing materials and supportive medicines for leprosy patients with plantar ulcers and wounds (provided under NLEP including to leprosy colonies)
Micro-cellular rubber (MCR) footwear: Protects insensitive feet from repeated trauma and plantar ulcers
Self-care training: patients taught to inspect insensitive limbs daily, soak and oil dry skin, protect from burns and trauma
Physiotherapy: active and passive exercises to prevent contractures, maintain joint mobility

2. Surgical Rehabilitation (Reconstructive Surgery - RCS): Corrects fixed deformities that cannot be reversed by physiotherapy:

Lagophthalmos: Lateral tarsorrhaphy, gold weight implantation
Claw hand: Flexor digitorum superficialis (FDS) tendon transfer
Foot drop: Tibialis posterior transfer (Lambrinudi procedure)
Wrist drop and thumb opposition deformity: Tendon transfer procedures
Saddle nose: Cosmetic rhinoplasty

Under NLEP: 83 centers (41 NGOs + 42 Government Medical Colleges) conduct RCS nationally. Financial support: Rs. 5,000 incentive per BPL patient undergoing RCS; Rs. 5,000 per surgery to government institutions.

3. Socio-economic Rehabilitation:

Vocational training and livelihood support
Micro-credit and self-help group formation
Anti-stigma and IEC (Information, Education, Communication) campaigns
ILEP (International Federation of Anti-Leprosy Associations): supports 36 NGOs for reconstructive surgery
Legal protection: leprosy is no longer a ground for divorce under Indian law (Dissolution of Muslim Marriages Act amendment, 2019)

4. Community-Based Rehabilitation (CBR):

ASHA worker involvement in detection and treatment completion
Household contact surveys
Integration with general health care system (since 2002-03)
Tiered system: primary (wound care, MCR footwear, referral) → secondary/tertiary (RCS, PMR centers)

ATYPICAL PRESENTATIONS OF PAUCIBACILLARY (PB) LEPROSY (4 Marks)

Definition: PB leprosy includes indeterminate, tuberculoid (TT), and borderline tuberculoid (BT) forms - up to 5 skin lesions and/or 1 nerve trunk, negative slit-skin smear.

Atypical Presentations:

1. Pure Neuritic (Neural) Leprosy:

Sensory loss ± motor deficit along a nerve trunk with no skin lesions
Accounts for 5-10% of leprosy in India and Nepal
Nerve involvement generally asymmetrical; may be single or multiple
Up to 1/3 of patients later develop skin lesions
Diagnosis: nerve biopsy showing epithelioid granulomas

2. Solitary Lesion Leprosy (Single Patch Leprosy):

Only one skin lesion - hypo/hyperpigmented patch
Treatment: Single-dose ROM therapy (Rifampicin 600 mg + Ofloxacin 400 mg + Minocycline 100 mg)

3. Reactional State as Presenting Feature:

Type 1 (Reversal Reaction) may be the first presentation
Sudden erythema, swelling, neuritis - the patient may not have noticed the original patch

4. Clinical Mimickers (Diagnostic Pitfalls):

Hypo/depigmented patches mimic: vitiligo, pityriasis alba, tinea versicolor, NLD
Annular lesions mimic: granuloma annulare, tinea corporis, DLE
Key clue: hypoesthesia + anhidrosis + absence of hair within the patch

5. Leprosy in Special Sites:

Earlobe infiltration, nasal mucosal lesions, eyebrow involvement
Purely neural involvement of a single small nerve branch mimicking nerve entrapment

6. Leprosy Immunosuppressed Host:

HIV coinfection can unmask leprosy or trigger immune reconstitution inflammatory syndrome (IRIS) presenting as a Type 1 reaction when ART is initiated

Q9. Prenatal Syphilis; Ulcerative STD and HIV Coinfection (10 Marks)

PRENATAL (CONGENITAL) SYPHILIS (6 Marks)

Epidemiology:

Congenital syphilis has resurged globally; ~21% of perinatal deaths in sub-Saharan Africa are attributable to it
Risk groups: mothers with no prenatal care, substance users, sex workers, those treated with non-penicillin regimens

Pathogenesis:

Treponema pallidum crosses the placenta from an infected mother (usually with early syphilis)
Placental transmission does not occur before the 4th month (Langhans layer acts as barrier)
Treatment before end of 2nd trimester almost always prevents adverse outcomes
Risk from untreated early maternal syphilis: 40% fetal death/miscarriage + 40% syphilitic infant
Fetal infection is rare when mother has had syphilis for >2 years

Classification:

Early congenital syphilis: Manifestations within first 2 years of life
Late congenital syphilis: Manifestations after age 2 years

Clinical Features - Early Congenital Syphilis:

2/3 neonates appear normal at birth - detected only by serology
Snuffles (syphilitic rhinitis): most frequent, often first sign - blood-stained nasal discharge, nasal obstruction; progressive ulceration causes saddle nose
Cutaneous lesions (30-60%): Morbilliform rash → fading copper-brown; pemphigus syphiliticus (bullae on palms/soles); mucous patches; condylomata lata
Hepatosplenomegaly, jaundice
Osteochondritis/periostitis: Wimberger sign (bilateral destruction of medial tibial metaphyses on X-ray)
Pseudoparalysis of Parrot: Immobility of limb from osteochondritis pain (mimics paralysis)
CNS: Meningitis, hydrocephalus
General appearance: Marasmic, fretful neonate with "old man face"

Clinical Features - Late Congenital Syphilis:

Hutchinson's Triad (pathognomonic): Interstitial keratitis + Hutchinson's teeth + 8th nerve (sensorineural) deafness
Hutchinson's teeth: Notched, barrel-shaped, peg-shaped upper central incisors (permanent teeth)
Interstitial keratitis: Most common (40-80%) - photophobia, lacrimation, corneal vascularization
Bone: Saber shins (anterior bowing of tibia from periostitis), Clutton's joints (painless bilateral synovitis of knees)
Saddle nose, Rhagades (perioral linear scars from healed early papules)
Neurosyphilis: Juvenile tabes dorsalis, seizures, intellectual disability
Stigmata: Higouménakis sign (unilateral SCM enlargement), Moon's molars (dome-shaped first molars)

Screening:

All pregnant women: serologic testing at first antenatal visit AND at delivery
Point-of-care RPR/VDRL tests used in resource-limited settings

Treatment of Congenital Syphilis:

Patient	Regimen
Neonate/infant	Aqueous crystalline penicillin G 200,000-300,000 U/kg/day IV/IM (50,000 U/kg every 4-6 hrs) x 10-14 days
Older children	Same OR benzathine penicillin G 50,000 U/kg IM single dose (max 2.4 MU)
Pregnant mother	Benzathine penicillin G 2.4 MU IM (dose per stage; second dose 1 week later may be given)

Penicillin is the ONLY drug proven effective; no validated alternative in pregnancy
Erythromycin and azithromycin are NOT recommended for any stage of syphilis

Common Preventable Failures:

No documented treatment of syphilis diagnosed before pregnancy
Absence of serologic testing during pregnancy
Late or no maternal treatment
Non-penicillin regimens used

ULCERATIVE STD AND HIV COINFECTION (4 Marks)

Core Concept: Genital ulcer disease (GUD) and HIV have a bidirectional, synergistic relationship - each amplifies the transmission and progression of the other.

Mechanism - Increased HIV Acquisition (HIV-negative with GUD):

Genital ulcers disrupt mucosal integrity, removing the first line of defense
HIV-positive immune cells (CD4+ T cells, macrophages) are recruited to the ulcer site in large numbers
Concentrated inflammatory infiltrate at the ulcer provides a highly susceptible target for HIV entry
Estimated risk increase: 2-5 fold per sexual act

Mechanism - Increased HIV Transmission (HIV-positive with GUD):

HIV is shed in high concentrations in ulcer exudate
HSV-2 shedding is dramatically increased in HIV-positive persons
HSV-2 co-infection affects 50-90% of HIV-positive patients
Syphilis coinfection increases HIV viral load AND decreases CD4 count, accelerating immunosuppression and disease progression

Specific STD-HIV Interactions:

Ulcerative STD	Causative Agent	Interaction with HIV
Genital Herpes (HSV-2)	Herpes simplex virus type 2	Most important global cofactor; bidirectional amplification; 50-90% of HIV+ affected
Syphilis	Treponema pallidum	Raises viral load, lowers CD4 count; accelerates immunosuppression; atypical syphilis presentations in HIV+
Chancroid	Haemophilus ducreyi	Major HIV transmission cofactor in sub-Saharan Africa
Lymphogranuloma Venereum	Chlamydia trachomatis L1-L3	Bubo and ulceration facilitate HIV entry
Donovanosis	Klebsiella granulomatis	Extensive ulceration = large HIV entry portal

Clinical Implications:

All GUD patients must be offered HIV testing (and vice versa)
Treatment of GUD reduces HIV transmission at the population level
Suppressive HSV-2 therapy (Acyclovir 400 mg BD) in HIV-positive patients reduces both HIV shedding and HSV recurrences
Modified syphilis treatment in HIV+ patients: some experts recommend 3 weekly doses of benzathine penicillin even for early syphilis
Condom promotion and partner notification are essential

Q10. STD Investigations; Gonorrhoea Complications (10 Marks)

STD INVESTIGATIONS (5 Marks)

Approach: STD investigations can be approached by pathogen category, serving both screening and confirmatory purposes.

A. Bacterial STDs:

1. Gonorrhoea (Neisseria gonorrhoeae):

Gram stain of discharge: Gram-negative intracellular diplococci; sensitivity 90-95% in symptomatic male urethritis, only ~50% in females and asymptomatic infections
Culture on Thayer-Martin medium (chocolate agar + antibiotics to suppress commensals): Gold standard; allows antibiotic sensitivity testing - critical in era of resistance
NAAT (Nucleic Acid Amplification Tests): Most sensitive and specific; uses urine, urethral, cervical, rectal, or pharyngeal swabs; preferred test at referral level

2. Chlamydia (Chlamydia trachomatis):

NAAT: First-line - urine or genital swab; sensitivity >95%
Cell culture in McCoy cells: Historical gold standard; technically demanding
EIA/ELISA antigen detection: Less sensitive than NAAT
Microimmunofluorescence (MIF): For LGV serology (L1-L3 serovars)

3. Syphilis (Treponema pallidum):

Dark-field microscopy: Direct visualization of motile spirochetes from primary chancre or secondary lesions - gold standard for active lesions
Non-treponemal tests (NTT): VDRL and RPR - screening and monitoring treatment response; titers fall with successful treatment; false positives in SLE, pregnancy, malaria, EBV
Treponemal tests: TPHA, FTA-ABS, TPPA - confirmatory; remain positive lifelong even after treatment (cannot be used to monitor response)
PCR: Available in specialized centers; useful for neurosyphilis (CSF), primary chancres

B. Viral STDs:

4. Genital Herpes (HSV-1/2):

Viral culture from vesicle base: Gold standard but sensitivity falls rapidly in healing lesions
Tzanck smear: Multinucleated giant cells - rapid, inexpensive, low sensitivity (~50%)
PCR/NAAT: Most sensitive, especially for late, atypical, or healing lesions; also used for CSF in HSV encephalitis
Type-specific IgG serology: Distinguishes HSV-1 from HSV-2; useful for diagnosis between episodes

5. HPV/Genital Warts:

Clinical diagnosis in most cases
Acetowhitening (3-5% acetic acid): Reveals subclinical lesions as white areas
Colposcopy + biopsy: For cervical/atypical lesions
HPV DNA typing (PCR): Identifies high-risk strains (HPV 16, 18)
Pap smear/Liquid-based cytology (LBC): Cervical cancer screening

C. Other Pathogens:

6. Chancroid (H. ducreyi):

Culture on selective enriched chocolate agar: Sensitivity only 50-60% even under ideal conditions
NAAT where available
Often a clinical/exclusion diagnosis

7. Trichomonas vaginalis:

Wet mount microscopy: Direct visualization of motile flagellated trichomonads; sensitivity 60-70%
Culture (InPouch TV): Gold standard; sensitivity ~95%
NAAT: Highest sensitivity

8. HIV Testing (mandatory in ALL STD patients):

4th generation Ag/Ab combination assay (screening) - detects p24 antigen + antibody
Western blot or NAAT (confirmatory)
CD4 count and viral load (staging and monitoring)

GONORRHOEA COMPLICATIONS (5 Marks)

Causative Agent: Neisseria gonorrhoeae - Gram-negative intracellular diplococcus, oxidase-positive

Complications are systematically classified as Local, Regional (ascending), Systemic (disseminated), and Neonatal:

A. LOCAL COMPLICATIONS IN MALES:

Epididymo-orchitis: Most common serious male complication; unilateral scrotal pain, swelling, tenderness; may lead to obstructive azoospermia and infertility
Prostatitis: Acute: urinary retention, perineal/rectal pain, tender boggy prostate; Chronic: perineal discomfort, obstructive symptoms
Cowperitis: Abscess of Cowper's (bulbourethral) glands; perineal swelling, pain on defecation, urinary retention
Tysonitis: Infection of Tyson's glands (preputial glands)
Periurethral abscess and Urethral stricture: Late fibrous complication from chronic inflammation; presents as poor urinary stream, dribbling; requires urethral dilatation or urethroplasty
Balanitis/Posthitis: Secondary infection of glans/prepuce

B. LOCAL COMPLICATIONS IN FEMALES:

Bartholinitis/Bartholin's abscess: Tender unilateral swelling at the 5 or 7 o'clock position of the vulva; fluctuant; may require incision and drainage or marsupialization
Skenitis: Infection of Skene's (paraurethral) glands
Cervicitis: Mucopurulent endocervical discharge, contact bleeding, cervical motion tenderness
Endometritis: Abnormal uterine bleeding, pelvic pain

C. REGIONAL/ASCENDING COMPLICATIONS (Pelvic Inflammatory Disease - PID):

Most important complication of gonorrhoea in women:

Ascending infection causes salpingitis, endometritis, and potentially tubo-ovarian abscess
Fitz-Hugh-Curtis Syndrome: Perihepatitis from transperitoneal spread; presents as RUQ pain; "violin-string" adhesions between liver capsule and anterior abdominal wall (pathognomonic finding at laparoscopy)

Consequences of PID:

Infertility: 25% after one episode; 50% after two; 75% after three episodes (tubal factor infertility)
Ectopic pregnancy: 10x increased risk from tubal scarring
Chronic pelvic pain: Long-term sequela
Recurrent PID: Each episode increases risk of all above complications

D. NEONATAL COMPLICATIONS:

Ophthalmia Neonatorum (Gonococcal Conjunctivitis):

Acquired during passage through infected birth canal
Onset: 2-5 days after birth (contrast with chlamydial ophthalmia: 5-14 days)
Presents as severe bilateral purulent conjunctivitis; can rapidly progress to corneal ulceration, perforation, and permanent blindness
Prophylaxis (Credé's method): 1% silver nitrate drops at birth; or erythromycin/tetracycline 0.5% eye ointment
Treatment: Ceftriaxone 25-50 mg/kg IV/IM single dose

E. DISSEMINATED GONOCOCCAL INFECTION (DGI):

Occurs in 0.5-3% of untreated gonorrhoea; more common in women; associated with complement deficiency states

Two-phase presentation:

Phase 1 - Bacteremic/Arthritis-Dermatitis Syndrome:

Tenosynovitis (especially fingers, wrists, ankles) - pathognomonic of DGI
Dermatitis: 1-20 scattered pustular, vesicular, hemorrhagic, or necrotic papulopustules on extremities
Polyarthralgias/migratory polyarthritis
Blood cultures often positive (50%)

Phase 2 - Septic Arthritis:

Purulent monoarthritis (knee most common; also wrist, ankle)
Blood cultures usually negative; joint fluid culture positive
Permanent joint damage if untreated

Rare but Life-threatening DGI Manifestations:

Gonococcal endocarditis: Aortic valve most commonly; high mortality; requires 4 weeks treatment
Gonococcal meningitis: Rare; requires high-dose IV penicillin/ceftriaxone
Perihepatitis (Fitz-Hugh-Curtis): As described above

Gonorrhoea Complication Summary Table:

Site/System	Complication	Key Feature
Male urethra	Stricture, abscess	Late scarring; poor stream
Epididymis	Epididymo-orchitis	Infertility risk
Female lower tract	Bartholinitis, cervicitis	5/7 o'clock abscess
Female upper tract	PID, salpingitis	Infertility, ectopic pregnancy
Peritoneum/liver	Fitz-Hugh-Curtis	Violin-string adhesions
Neonate eye	Ophthalmia neonatorum	Blindness risk; onset 2-5 days
Systemic	DGI - arthritis-dermatitis	Tenosynovitis + pustules
Heart/CNS	Endocarditis, meningitis	Rare; high mortality

Current Treatment of Gonorrhoea (WHO/CDC):

Uncomplicated urogenital/anorectal/pharyngeal: Ceftriaxone 500 mg IM single dose (1g if weight >150 kg)
If chlamydia not excluded: add Doxycycline 100 mg BD x 7 days
DGI: Ceftriaxone 1g IV/IM daily x minimum 7 days
Gonococcal endocarditis/meningitis: Ceftriaxone 1-2g IV every 12-24 hours for 4 weeks (endocarditis) / 10-14 days (meningitis)
Ophthalmia neonatorum: Ceftriaxone 25-50 mg/kg IV/IM single dose
Resistance note: Fluoroquinolone and penicillin resistance now widespread; XDR (ceftriaxone-resistant) strains emerging - culture + sensitivity essential for treatment failures

Sources: Goldman-Cecil Medicine International Edition; Fitzpatrick's Dermatology (Wolff, 8th ed.); Dermatology 2-Volume Set (Lebwohl, 5th ed.); Andrews' Diseases of the Skin (James et al.); Harrison's Principles of Internal Medicine (22nd ed., 2025, McGraw Hill); Park's Textbook of Preventive and Social Medicine; Campbell-Walsh Urology.

This is a shared conversation. Sign in to Orris to start your own chat.